Development of a therapeutic vaccine for the treatment of cocaine addiction.
No pharmacotherapies have yet been approved for the treatment of cocaine addiction. One new approach is to block the effects of cocaine with anti-cocaine antibodies induced by a therapeutic cocaine vaccine. A cocaine vaccine has been developed which induces a cocaine-specific antibody response in rodents. The antibody binds to cocaine in the circulation and can be shown to inhibit the ability of cocaine to enter the brain. Furthermore, anti-cocaine antibody can inhibit cocaine self-administration in rats. These data suggest that a cocaine vaccine may be a powerful therapeutic tool. The intent is to immunized motivated patients with the vaccine as part of a comprehensive treatment program. If the patient uses cocaine after being vaccinated, the antibody will inhibit the reinforcing activity of cocaine and decrease the likelihood of relapse.
Fox
B S
BS
ImmuLogic Pharmaceutical Corporation, Waltham, MA 02154, USA. FoxB@ImmuLogic.com
D000818:Animals; D000936:Antigen-Antibody Complex / Q000494:pharmacology; D016739:Behavior, Addictive / Q000188:drug therapy; D001812:Blood-Brain Barrier; D001923:Brain Chemistry; D002352:Carrier Proteins / Q000494:pharmacology; D003042:Cocaine / Q000008:administration & dosage / Q000097:blood / Q000276:immunology* / Q000493:pharmacokinetics; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D006801:Humans; D007116:Immunization, Passive; D051379:Mice; D051381:Rats; D012651:Self Medication; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D014612:Vaccines / Q000494:pharmacology*
D000936:Antigen-Antibody Complex; D002352:Carrier Proteins; D014612:Vaccines; D012710:Serum Albumin, Bovine; D003042:Cocaine